M617

M617 was created as a galanin receptor 1 preferring agonist by fusing the active N-terminal region of galanin to a bradykinin-derived C-terminal segment, yielding a chimeric peptide with markedly greater selectivity for GalR1 over GalR2. This selectivity made it a counterpart to the GalR2-preferring galanin(2-11), and together the two allow researchers to assign galanin's actions to specific receptor subtypes.

In pain research, M617 has clarified GalR1's antinociceptive role. In a rat model of neuropathic pain, GalR1 expression was upregulated in the nucleus accumbens, and intra-accumbal M617 produced a dose-dependent increase in hindpaw withdrawal latency to thermal and mechanical stimuli; this effect was attenuated by the GalR1/2 antagonist M35, and M617's antinociception was stronger in neuropathic than in intact animals, indicating that GalR1 signaling in the accumbens contributes to pain suppression ^[1]. These findings positioned GalR1 agonism as a potential analgesic mechanism within limbic pain-modulatory circuitry.

M617 has also illuminated galanin's metabolic actions. Central administration of M617 to type 2 diabetic rats increased expression and content of the glucose transporter GLUT4 in cardiac muscle while lowering fasting glucose and insulin, implying that central GalR1 activation improves cardiac glucose uptake ^[2]. In skeletal muscle, central M617 raised glucose infusion rates in hyperinsulinemic clamps and increased GLUT4 translocation via the Akt and AS160 signaling pathway, mitigating insulin resistance ^[3]. This contrasts instructively with peripheral GalR1 agonism by systemic analogs such as NAX-5055, which raises blood glucose, underscoring that GalR1's metabolic effects depend on site of action. M617 remains a mechanistic research peptide rather than a drug candidate.

M617 is a preclinical research peptide without human safety data. Because GalR1 agonism has divergent metabolic effects depending on where it acts, with central administration improving glucose handling but peripheral GalR1 activation tending to raise blood glucose, systemic effects would be difficult to predict and are unstudied in humans. No toxicology, pharmacokinetic, or reproductive data exist, and it is administered experimentally by central routes. It is not a consumer product.

M617 was developed as part of a series of chimeric galanin analogs designed to achieve receptor-subtype selectivity, providing a GalR1-preferring counterpart to GalR2-preferring tools. It has since been used extensively by pain and metabolism laboratories, including Chinese groups studying galanin receptors in diabetes and neuropathic pain, to attribute specific physiological effects to GalR1 activation.

M617 is a respected subtype-selective reagent in the galanin field, frequently paired with galanin(2-11) and the antagonist M35 to build receptor-specific interpretations. Its contributions to understanding GalR1 in pain and glucose metabolism are well cited, but it has no therapeutic development and is unknown outside academic pharmacology. It exists only as a research peptide.